Answers are grounded in this paper and cite their sources.
Background In the HiSCO-03 trial of adjuvant uracil–tegafur and leucovorin in patients aged ≥ 80 years with stage III colorectal cancer, the treatment completion rate was lower than expected. This final analysis evaluated long-term outcomes and risk factors for treatment discontinuation. Methods Of 69 enrolled patients, 65 were included in the survival analysis. In exploratory analyses, skeletal muscle mass was measured on preoperative computed tomography at the third lumbar vertebra, and risk factors for discontinuation due to adverse events or patient refusal were analyzed using logistic regression in 45 patients, excluding those who discontinued treatment because of recurrence. Results The 3-year disease-free survival rate was 70.6%, and the 5-year overall, recurrence-free, and disease-free survival rates were 75.9%, 64.5%, and 61.4%, respectively. Of the 45 patients, 30 completed and 15 discontinued treatment. In multivariable analysis, female sex (odds ratio 7.75, 95% confidence interval 1.68–56.59) and low skeletal muscle mass (odds ratio 9.69, 95% confidence interval 1.84–78.11) were independent risk factors for discontinuation. Survival did not differ between patients who completed and those who discontinued treatment. Conclusions In patients aged ≥ 80 years with stage III colorectal cancer, adjuvant uracil–tegafur and leucovorin achieved a 3-year disease-free survival rate comparable to those reported in younger patients. Low skeletal muscle mass and female sex were associated with treatment discontinuation. These factors may help identify, before treatment, patients who are likely to tolerate adjuvant chemotherapy and those who need early supportive care. Trial registration jRCTs061180087 (registered 22 March 2019 retrospectively registered).
No takes yet. Share an insight, caveat, or question.
Moriuchi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: